Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, and Eosinophilic Disorders and Syndromes.
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> Rearrangement
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms
Clinical utility of targeted next‐generation sequencing panel in routine diagnosis of hereditary hemolytic anemia: A national reference laboratory experience
Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group
The genetic landscape of germline<i>DDX41</i>variants predisposing to myeloid neoplasms
Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation
FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>) Rearrangement (MLN<i>FGFR1</i>): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients
Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent <i>KIT</i> D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)
AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)
Ophthalmic Manifestations Of Coronavirus (COVID-19)
StatPearls 2020cited by 68position: middle
Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement
Coexisting and cooperating mutations in NPM1 -mutated acute myeloid leukemia
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
Clinical utility of next‐generation sequencing in the diagnosis of hereditary haemolytic anaemias
Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy
DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia
Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia